CHNA
Loncar China BioPharma ETF
CHNA
CHNA
Delisted
CHNA was delisted on the 20th of October, 2023.
6 hedge funds and large institutions have $1.9M invested in Loncar China BioPharma ETF in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Jane Street
New York
|
+$619K |
| 2 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
+$292K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$21K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$16.5K |
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $1.49M | +$619K | +20,148 | +71% |
|
|
FEM
2
Fulcrum Equity Management
Plano,
Texas
| $292K | +$292K | +9,504 | New |
|
3
Morgan Stanley
New York
| $61K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $27K | +$16.5K | +541 | +158% |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| $21K | +$21K | +684 | New |
|